Otamixaban


CAS No. : 193153-04-7

Otamixaban,193153-04-7
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I002471
Synonyms:methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
Molecular Formula:C25H26N4O4
Molecular Weight:446.53
Target:Thrombin
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:I002471
Cas No:193153-04-7
Product-Name:Otamixaban
IUPAC Name:methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
InChI:InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
InChIKey:PFGVNLZDWRZPJW-OPAMFIHVSA-N
SMILES:CC(C(CC1=CC=CC(=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]

Otamixaban(cas 193153-04-7) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.

1. J Pharm Anal. 2014 Jun;4(3):197-204. doi: 10.1016/j.jpha.2013.10.001. Epub 2013 Nov 26.
Enantiomeric characterization and structure elucidation of Otamixaban.
Shen J(1), Yang J(1), Heyse W(2), Schweitzer H(2), Nagel N(2), Andert D(2), Zhu C(1), Morrison V(1), Nemeth GA(1), Chen TM(1), Zhao Z(1), Ayers TA(1), Choi YM(1).
Author information:
(1)Sanofi, 1041 Route 202-206, Bridgewater, NJ 08807, United States. (2)Sanofi, Industriepark Hoechst Bldg., D-65926 Frankfurt, Germany.
Otamixaban is a potent (Ki=0.5 nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric characterization has been accomplished using vibrational circular dichroism (VCD) spectroscopy. Selected by a spectrum similarity index, the calculated spectra of several higher energy conformers were found to match well with the observed spectra. The characteristic IR bands of these conformers were also identified and attributed to the solvation effect. Combined with both the single crystal x-ray diffraction results for an intermediate and the proton NMR study, the absolute configuration of Otamixaban is unambiguously determined to be (R,R).

2. Lancet. 2009 Sep 5;374(9692):762-4. doi: 10.1016/S0140-6736(09)61529-4. Epub 2009 Aug 28.
Otamixaban in acute coronary syndromes.
Eikelboom JW(1), Weitz JI.
Author information:
(1)Thrombosis Service, Hamilton General Hospital, Hamilton, ON, Canada L8L 2X2. eikelbj@mcmaster.ca

3. Clin Pharmacol Ther. 2006 Dec;80(6):691-702.
Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Hinder M(1), Frick A, Jordaan P, Hesse G, Gebauer A, Maas J, Paccaly A.
Author information:
(1)Science & Medical Affairs, Sanofi-Aventis, Frankfurt am Main, Germany. markus.hinder@sanofi-aventis.com
BACKGROUND: New anticoagulants that combine effective anticoagulation with low bleeding rates are still sought after. We investigated the safety, pharmacokinetics, and pharmacodynamics of otamixaban, a direct factor Xa inhibitor, in patients with stable coronary artery disease.
METHODS: This was a randomized, placebo-controlled, double-blind, multicenter study in 119 patients with stable coronary artery disease taking maintenance doses of their comedication. Of these patients, 50% had mild renal impairment (creatinine clearance >45 mL/min but <80 mL/min). Patients were randomized in a 4:1 ratio to receive either otamixaban or placebo as a 1-minute bolus followed by a 24-hour continuous infusion. Anti-factor Xa activity, clotting times (activated partial thromboplastin time, dilute prothrombin time, Russell's viper venom test), and international normalized ratio were measured.
RESULTS: All patients completed the study according to the protocol. No major or minor bleeding occurred according to Thrombosis in Myocardial Infarction criteria. Anti-factor Xa activity and anticoagulant effect were measurable early after the start of the infusion and remained during the infusion. Upon cessation, these effects declined rapidly and returned to baseline within 6 hours after the end of infusion. Anti-factor Xa activity coincided with the otamixaban plasma concentrations. The fold changes from baseline at the end of infusion with regard to the clotting times ranged from 1.7 to 4.4 (1.15 for placebo), 1.29 to 3.15 (0.98 for placebo), and 1.19 to 2.11 (0.94 for placebo) for Russell's viper venom test, dilute prothrombin time, and activated partial thromboplastin time, respectively, and ranged from 0.94 to 1.70 (0.94 for placebo) for the international normalized ratio.
CONCLUSION: In patients with stable coronary artery disease taking maintenance doses of their usual concomitant medication, otamixaban exerts a rapid onset of anticoagulation and anti-factor Xa activity. Our data provide evidence that further studies are warranted to investigate the safety and efficacy of otamixaban in the target population.
Related Products
  • CAS No. :9041-08-1
    Product Name:

    Heparin sodium 180 U/mg

    Cat No: A000895 View details
  • CAS No. :74863-84-6
    Product Name:

    Argatroban

    Cat No: I004778 View details
  • CAS No. :
    Product Name:

    Dabigatran D4 hydrochloride

    Cat No: I005837 View details
  • CAS No. :211915-06-9
    Product Name:

    Dabigatran etexilate

    Cat No: I002632 View details